H.C. Wainwright analyst Michael King maintained a Buy rating on Agios Pharma (NASDAQ:AGIO) on Tuesday, setting a price target of $88, which is approximately 43.63% above the present share price of $61.27.
King expects Agios Pharma to post earnings per share (EPS) of $26.95 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Moderate Buy rating of shares in Agios Pharma, with an average price target of $70.33.
The analysts price targets range from a high of $88 to a low of $58.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $0 and a net profit of -$91.22 million. The company's market cap is $3.77 billion.
According to TipRanks.com, H.C. Wainwright analyst Michael King is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 28.9% and a 57.58% success rate.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.